Country: Slóvenía
Tungumál: enska
Heimild: HMA (Heads of Medicines Agencies)
toltrazuril 50 mg/ml
Bayer HealthCare
QP51AJ01
Oral suspension
toltrazuril
Cattle Non Lactating
2012-02-02
Filename: Dokument1 1/13 SUMMARY OF PRODUCT CHARACTERISTICS Baycox Bovis RENEWAL DK/V/0109/001/R/001 DAY 90 Dokument1 2/13 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Baycox Bovis 50mg/ml oral suspension 2. QUALITATIVE AND QUANTITATIVE COMPOSITION 1 ml contains: Active substance: Toltrazuril 50.0 mg EXCIPIENT(S): Sodium benzoate (E211) 2.1 mg Sodium propionate (E281) 2.1 mg For a full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM Oral suspension White or yellowish suspension 4. CLINICAL PARTICULARS 4.1 TARGET SPECIES Cattle (calves on dairy farms) 4.2 INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES For the prevention of clinical signs of coccidiosis and reduction of coccidia shedding in housed calves replacing cows producing milk for human consumption (dairy cows) on farms with a confirmed history of coccidiosis caused by _Eimeria bovis_ or _Eimeria zuernii_. 4.3 CONTRAINDICATIONS For environmental reasons: Do not use in calves weighing more than 80 kg bodyweight. Do not use in fattening units such as veal or beef calves For more details see sections 4.5, other precautions and section 5, environmental properties. 4.4 SPECIAL WARNINGS As with any antiparasiticide frequent and repeated use of antiprotozoals from the same class may lead to the development of resistance. It is recommended to treat all calves in a pen Hygienic measures may reduce the risk of bovine coccidiosis. It is therefore, recommended to improve concomitantly the hygienic conditions i Lestu allt skjalið